# reload+after+2024-01-23 02:44:08.980252
address1§1 Ashley Road
address2§3rd Floor
city§Altrincham
zip§WA14 2DT
country§United Kingdom
phone§44 203 9206789
website§https://www.centessa.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
fullTimeEmployees§75
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Saurabh  Saha M.D., Ph.D.', 'age': 46, 'title': 'CEO & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 957672, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gregory M. Weinhoff M.B.A., M.D.', 'age': 52, 'title': 'Principal Accounting Officer & CFO', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 655004, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David M. Chao Ph.D.', 'age': 55, 'title': 'Chief Administrative Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 655004, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tia L. Bush', 'age': 52, 'title': 'Chief Technology & Quality Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kristen K. Sheppard Esq., J.D.', 'title': 'Senior Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Iqbal J. Hussain L.L.B.', 'age': 42, 'title': 'General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen M. Anderson', 'age': 55, 'title': 'Chief People Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Antoine  Yver M.D., M.Sc.', 'age': 65, 'title': 'Executive VP & Chairman of Development', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 449579, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David John Grainger Ph.D.', 'age': 54, 'title': 'Chief Innovation Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Harris L. Rotman Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.248
currency§USD
dateShortInterest§1702598400
forwardEps§-1.8
exchange§NMS
quoteType§EQUITY
shortName§Centessa Pharmaceuticals plc
longName§Centessa Pharmaceuticals plc
firstTradeDateEpochUtc§1622208600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§8.0
targetMeanPrice§13.0
targetMedianPrice§11.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§8.918
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
